10ᵗʰ International Symposium on Hodgkin Lymphoma
back to
back to
Program
Schedule
22.10.2016
23.10.2016
24.10.2016
25.10.2016
Scientific Committee
Media
Photos
Videos
Downloads
Abstracts
Newsletters
Acknowledgements
Sponsors
Other Archives
ISHL12
Update on Hodgkin Lymphoma
ISHL11
ISHL10
ISHL9
ISHL8
ISHL7
Back to video list
Pembrolizumab for relapsed / refractory classical Hodgkin Lymphoma (R / R cHL): multicohort, phase 2 KEYNOTE-087 study
Speaker
Craig H. Moskowitz
Session
Relapsed HL
Others Talks of this Session
Brentuximab vedotin in relapsed HL
Clinical results with anti-PD(L)1 antibodies in HL
CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation
TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed / refractory Hodgkin Lymphoma (HL). A phase 1 dose- escalation study
This website uses cookies to ensure you get the best experience on our website. By using our site you agree to our use of cookies.
Learn more
Got it!